On Wednesday, Applied Materials, Inc. (NASDAQ:AMAT)’s shares declined -0.77% to $16.07.
Applied Materials, Inc. (AMAT) is currently valued at $19.44 billion. The company has 1.20 billion shares outstanding and 87.60% shares of the company were owned by institutional investors. The company has 2.02 value in price to sale ratio while price to book ratio was recorded as 2.46. The company exchanged hands with 20.92 million shares as compared to its average daily volume of 16.83 million shares. It beta stands at 1.88.
Applied Materials, Inc. (Applied) provides manufacturing equipment, services and software to the global semiconductor, flat panel display, solar photovoltaic (PV) and related industries. Applied operates in four segments: Silicon Systems Group, Applied Global Services, Display, and Energy and Environmental Solutions.
Delta Air Lines, Inc. (NYSE:DAL)’s shares dropped -1.46% to $49.42.
Delta Air Lines, Inc. (DAL) has beta value of 0.85. The company has the market capitalization of $39.44 billion. Return on assets ratio of the company was 5.30% while its return on equity ratio was 30.00%. ATR value of company was 1.30 while stock volatility for week was 2.32% while for month was 2.91%. Debt to equity ratio of the company was -0.85 and its current ratio was -0.70.
Delta Air Lines, Inc. (Delta) provides planned air transportation for passengers and cargo throughout the United States and around the world. The Company’s route network is centered on a system of hub and international gateway airports that it operates in Amsterdam, Atlanta, Detroit, Los Angeles, Minneapolis-St. Paul, New York-LaGuardia, New York-JFK, Paris-Charles de Gaulle, Salt Lake City, Seattle and Tokyo-Narita.
At the end of Wednesday’s trade, Boston Scientific Corporation (NYSE:BSX)‘s shares showed no change to $17.19.
Boston Scientific Corporation (BSX) offered 33.30% EPS for prior five years. The company has -2.40% return on equity value while its ROI ratio was 0.80%. The company has $23.10 billion market capitalizations and the institutional ownership was 91.70%. Its price to book ratio was 3.50. Volatility of the stock was 1.99% for the week while for the month booked as 2.57%.
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which comprises Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.